Ocriplasmin (Approved), which targets FN1 and is used to treat vitreomacular adhesion, and two drugs targeting TGFB1, foreskin keratinocyte (Approved), a treatment used to accelerate wound healing, and terazosin (Approved), a medication for benign prostatic hyperplasia and hypertension, may have potential for repurposing in the treatment of atherosclerosis and cardiovascular diseases. The gene discussed is TGFB1; the disease is benign prostatic hyperplasia.